Member Info for soulac

Can’t get a live quote,

3p should be tested quickly, imo

Offered 2.45 to sell, tick up coming

There’s 135 million shares and 32% are held by investors, only 80 million in free float

Darrin Disley is a seasoned life sciences entrepreneur with a history of value creation in the UK market. His most notable achievement is leading gene editing company Horizon Discovery from start-up phase in 2007 to a £68 million AIM IPO in 2014 and growing the business to generate significant revenues with a global presence before stepping down to pursue other interests in 2018. Horizon was eventually acquired by PerkinElmer in 2021 for a total Enterprise value of £296 million. Roquefort Therapeutics is pleased to have Dr Disley leading the business and his significant expertise will be of benefit to the Company going forward.

The trades where at 9,40am 9.45am and 9.46am

There where 3 trades of 2.2 million all at 3p

3p on the ask

This was 4.5p in December that was without any of the 30 million in sales,

Looks like it’s about to breakout, imo

Bid needs to move up,

Plus all the other things they have

30 million = 25p a share

Only about 80 million shares in free float,

10k buy

3 February 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Share Purchase Agreement Signed - Sale of Lyramid

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, is pleased to announce the signing of a binding share purchase agreement (the "SPA") for the sale of its wholly owned subsidiary Lyramid Pty Ltd ("Lyramid") to Pleiades Pharma Limited ("Pleiades") for a consideration amount of US$10.8 million (the "Transaction"). This announcement follows the signing of a term sheet with Pleiades, as announced on 2 January 2025.

Principal Transaction Terms

The SPA includes the following principal terms:

· Sale of 100% of the issued share capital of Lyramid to Pleiades;

· Consideration amount of US$10.8 million consisting of equity in Pleiades, together with the potential for upfront cash (to be finalised at Transaction completion); and

· Completion is contingent inter alia on Pleaides completing a current fundraising round and finalising certain in-licensing transactions no later than 30 June 2025.

Following completion of the Transaction, Roquefort Therapeutics will hold a material equity position in Pleiades, a well-funded private company with a portfolio of clinical assets and pre-clinical programs.

From last month, worth watching

https://www.youtube.com/watch?v=3FTpl4GWDco

Should st To move back up, been NT to sell for the last 15 minutes

Maybe this the last of the sell going through, you never know what mms are up to

MMs games ,